company background image
PXH logo

Pixium Vision DB:PXH Stock Report

Last Price

€0.25

Market Cap

€1.5m

7D

0%

1Y

-85.8%

Updated

07 Mar, 2024

Data

Company Financials

PXH Stock Overview

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application.

PXH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Pixium Vision SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pixium Vision
Historical stock prices
Current Share Price€0.25
52 Week High€7.55
52 Week Low€0.041
Beta0.95
1 Month Change-32.80%
3 Month Change400.00%
1 Year Change-85.84%
3 Year Change-99.73%
5 Year Change-99.69%
Change since IPO-99.94%

Recent News & Updates

Recent updates

Shareholder Returns

PXHDE Medical EquipmentDE Market
7D0%-0.6%1.6%
1Y-85.8%2.8%6.4%

Return vs Industry: PXH underperformed the German Medical Equipment industry which returned 6.8% over the past year.

Return vs Market: PXH underperformed the German Market which returned 0.4% over the past year.

Price Volatility

Is PXH's price volatile compared to industry and market?
PXH volatility
PXH Average Weekly Movement91.4%
Medical Equipment Industry Average Movement5.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PXH's share price has been volatile over the past 3 months.

Volatility Over Time: PXH's weekly volatility has decreased from 170% to 91% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201140Lloyd Diamondhttps://www.pixium-vision.com

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh.

Pixium Vision SA Fundamentals Summary

How do Pixium Vision's earnings and revenue compare to its market cap?
PXH fundamental statistics
Market cap€1.53m
Earnings (TTM)-€10.52m
Revenue (TTM)€1.80m

0.9x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PXH income statement (TTM)
Revenue€1.80m
Cost of Revenue€0
Gross Profit€1.80m
Other Expenses€12.32m
Earnings-€10.52m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin100.00%
Net Profit Margin-584.66%
Debt/Equity Ratio-127.5%

How did PXH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.